Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 3/2013

01-09-2013 | Review Article

Role of BAX for outcome prediction in gastrointestinal malignancies

Authors: Filippo Pietrantonio, Pamela Biondani, Elisa Ciurlia, Giuseppe Fanetti, Anna Tessari, Gaia Bertarelli, Ilaria Bossi, Valeria Musella, Flavia Melotti, Maria Di Bartolomeo, Francesca Valvo, Alessandro Pellegrinelli, Massimo Milione, Federica Perrone, Filippo de Braud

Published in: Medical Oncology | Issue 3/2013

Login to get access

Abstract

Our group and numerous others have shown in both preclinical and clinical studies that the proapoptotic mediator BAX may be deregulated through gene mutation or loss of protein expression, affecting resistance to chemotherapy and radiotherapy in several cancer types. However, BAX is also involved in cancer development and may related to prognosis, independently of treatment outcome. The clinical impact of BAX status in gastrointestinal malignancies remains controversial, although it is generally hypothesized that high expression may be a positive prognostic factor and predict increased efficacy of chemotherapy (with particular regard to platinum derivatives). The present review aims to provide updated information on BAX as potential prognostic and/or predictive biomarker in gastroesophageal and colorectal cancers, as well as in other less studied gastrointestinal malignancies.
Literature
1.
Miyashita T, Reed JC. Tumor suppressor TP53 is a direct transcriptional activator of the human BAX gene. Cell. 1995;80(2):293–9.PubMedCrossRef
2.
Raffo AJ, Kim AL, Fine RL. Formation of nuclear BAX/TP53 complexes is associated with chemotherapy induced apoptosis. Oncogene. 2000;19(54):6216–28.PubMedCrossRef
3.
Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius VM, Niskanen E, et al. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res. 1995;55:4471–8.PubMed
4.
Kupryjańczyk J, Szymańska T, Madry R, Timorek A, Stelmachów J, Karpińska G, et al. Evaluation of clinical significance of TTP53, BCL2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen. Br J Cancer. 2003;88(6):848–54.PubMedCrossRef
5.
Gascoyne RD, Krajewska M, Krajewski S, Connors JM, Reed JC. Prognostic significance of Bax protein expression in diffuse aggressive non-Hodgkin’s lymphoma. Blood. 1997;90(8):3173–8.PubMed
6.
Duval A, Hamelin R. Mutations at coding repeat sequences in mismatch repair-deficient human cancers: toward a new concept of target genes for instability. Cancer Res. 2002;62:2447–54.PubMed
7.
Rampino N, Yamamoto H, lonov Y, Li Y, Sawai H, Reed JC, Perucho M. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science. 1996;275:967–9.CrossRef
8.
Yin C, Knudson CM, Korsmeyer SJ, Van Dyke T. BAX suppresses tumorigenesis and stimulates apoptosis in vivo. Nature. 1997;385:637–40.PubMedCrossRef
9.
Jansson A, Sun XF. BAX expression decreases significantly from primary tumor to metastasis in colorectal cancer. J Clin Oncol. 2002;20:811–6.PubMedCrossRef
10.
Yamamoto H, Sawai H, Weber TK, Rodriguez-Bigas MA, Perucho M. Somatic frameshift mutations in DNA mismatch repair and proapoptosis genes in hereditary nonpolyposis colorectal cancer. Cancer Res. 1998;58(5):997–1003.PubMed
11.
Schelwies K, Sturm I, Grabowski P, Scherübl H, Schindler I, Hermann S, et al. Analysis of TP53/BAX in primary colorectal carcinoma: low BAX protein expression is a negative prognostic factor in UICC stage III tumors. Int J Cancer. 2002;99(4):589–96.PubMedCrossRef
12.
Sarbia M, Bittinger F, Grabellus F, Verreet P, Dutkowski P, Willers R, et al. Expression of BAX, a pro-apoptotic member of the BCL2 family, in esophageal squamous cell carcinoma. Int J Cancer. 1997;73(4):508–13.PubMedCrossRef
13.
Ikeguchi M, Maeta M, Kaibara N. BAX expression as a prognostic marker of postoperative chemoradiotherapy for patients with esophageal cancer. Int J Mol Med. 2001;7:413–7.PubMed
14.
Sturm I, Petrowsky H, Volz R, Lorenz M, Radetzki S, Hillebrand T, et al. Analysis of TP53/BAX/p16(ink4a/CDKN2) in esophageal squamous cell carcinoma: high BAX and p16(ink4a/CDKN2) identifies patients with good prognosis. J Clin Oncol. 2001;19(8):2272–81.PubMed
15.
Natsugoe S, Matsumoto M, Okumura H, Nakashima S, Sakamoto F, Sakita H, et al. BAX and Bcl-X(L) expression are not related to prognosis in patients with advanced esophageal squamous cell carcinoma. Cancer Lett. 2001;174:91–7.PubMedCrossRef
16.
Urschel JD, Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg. 2003;185:538–43.PubMedCrossRef
17.
Berger AC, Farma J, Scott WJ, Freedman G, Weiner L, Cheng JD, et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol. 2005;23:4330–7.PubMedCrossRef
18.
Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001;19:305–13.PubMed
19.
Sarbia M, Stahl M, Fink U, Willers R, Seeber S, Gabbert HE. Expression of apoptosis-regulating proteins and outcome of esophageal cancer patients treated by combined therapy modalities. Clin Cancer Res. 1998;4(12):2991–7.PubMed
20.
Gibson MK, Abraham SC, Wu TT, Burtness B, Heitmiller SF, Health E, et al. Epidermal growth factor receptor, TP53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated preoperative chemoradiotherapy. Clin Cancer Res. 2003;9:6461–8.PubMed
21.
Kang SY, Han JH, Lee KJ, Choi JH, Park JI, Kim HI, et al. Low expression of BAX predicts poor prognosis in patients with locally advanced esophageal cancer treated with definitive chemoradiotherapy. Clin Cancer Res. 2007;13:4146–53.PubMedCrossRef
22.
Farkas R, Pozsgai E, Bellyei SZ, Cseke L, Szigeti A, Vereczkei A, et al. Correlation between tumor-associated proteins and response to neoadjuvant treatment in patients with advanced squamous-cell esophageal cancer. Anticancer Res. 2011;31(5):1769–75.PubMed
23.
Liu HF, Liu WW, Fang DC, Men RP. Expression and significance of proapoptotic gene BAX in gastric carcinoma. World J Gastroenterol. 1999;1999(5):15–7.
24.
Anagnostopoulos GK, Stefanou D, Arkoumani E, Chalkley L, Karagiannis J, Paraskeva K, et al. Expression of BAX protein in gastric carcinomas. A clinicopathological and immunohistochemical study. Acta Gastroenterol Belg. 2007;70:285–9.PubMed
25.
Liu X, Cai H, Huang H, Long Z, Shi Y, Wang Y. The prognostic significance of apoptosis-related biological markers in Chinese gastric cancer patients. PLoS One. 2011;6(12):e29670.PubMedCrossRef
26.
Nakata B, Muguruma K, Hirakawa K, Chung YS, Yamashita Y, Inoue T, et al. Predictive value of BCL2 and BAX protein expression for chemotherapeutic effect in gastric cancer: a pilot study. Oncology. 1998;55:543–7.PubMedCrossRef
27.
Muguruma K, Nakata B, Hirakawa K, Yamashita Y, Onoda N, Inoue T, et al. TP53 and BAX protein expression as predictor of chemotherapeutic effect in gastric carcinoma. Gan To Kagaku Ryoho. 1998;25(3):400–3.PubMed
28.
Jeong SH, Han JH, Kim JH, Ahn MS, Hwang YH, Lee HW, et al. BAX predicts outcome in gastric cancer patients treated with 5-fluorouracil, leucovorin, and oxaliplatin palliative chemotherapy. Dig Dis Sci. 2011;56:131–8.PubMedCrossRef
29.
Pietrantonio F, Biondani P, de Braud F, Pellegrinelli A, Bianchini G, Perrone F. el al. BAX expression is predictive of favorable clinical outcome in chemonaive advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimen. Transl Oncol. 2012;5(3):155–9.PubMed
30.
Osada S, Saji S, Kuno T. Clinical significance of combination study of apoptotic factors and proliferating cell nuclear antigen in estimating the prognosis of hepatocellular carcinoma. J Surg Oncol. 2004;85:48–54.PubMedCrossRef
31.
Garcia EJ, Lawson D, Cotsonis G, Cohen C. Hepatocellular carcinoma and markers of apoptosis (BCL2, BAX, bcl-x): prognostic significance. Appl Immunohistochem Mol Morphol. 2002;10(3):210–7.PubMedCrossRef
32.
Ikeguchi M, Hirooka Y, Kaibara N. Quantitative analysis of apoptosis-related gene expression in hepatocellular carcinoma. Cancer. 2002;95(9):1938–45.PubMedCrossRef
33.
Romani AA, Soliani P, Desenzani S, Borghetti AF, Crafa P. The associated expression of maspin and BAX proteins as a potential prognostic factor in intrahepatic cholangiocarcinoma. BMC Cancer. 2006;6:255.PubMedCrossRef
34.
Karamitopoulou E, Tornillo L, Zlobec I, Cioccari L, Carafa V, Borner M, Schaffner T, Brunner T, Diamantis I, Zimmermann A, Terracciano L. Clinical significance of cell cycle- and apoptosis-related markers in biliary tract cancer. Am J Clin Pathol. 2008;130:780–6.PubMedCrossRef
35.
Smith RA, Tang J, Tudur-Smith C, Neoptolemos JP, Ghaneh P. Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer. Br J Cancer. 2011;104(9):1440–51.PubMedCrossRef
36.
Friess H, Lu Z, Graber HU, Zimmermann A, Adler G, Korc M, Schmid RM, Büchler MW. BAX, but not BCL2, influences the prognosis of human pancreatic cancer. Gut. 1998;43(3):414–21.PubMedCrossRef
37.
Magistrelli P, Coppola R, Tonini G, Vincenzi G, Santini D, Borzomati D, et al. Apoptotic index or a combination of BAX/BCL2 expression correlate with survival after resection of pancreatic adenocarcinoma. J Cell Biochem. 2006;97:98–108.PubMedCrossRef
38.
Dong M, Zhou JP, Zhang H, Guo KJ, Tian YL, Dong YT. Clinicopathological significance of BCL2 and BAX protein expression in human pancreatic cancer. World J Gastroenterol. 2005;11(18):2744–7.PubMed
39.
Nio Y, Iguchi C, Yamasawa K, Sasaki S, Takamura M, Toga T, et al. Apoptosis and expression of BCL2 and BAX proteins in invasive ductal carcinoma of the pancreas. Pancreas. 2001;22(3):230–9.PubMedCrossRef
40.
Katkoori VR, Suarez-Cuervo C, Shanmugam C, Jhala NC, Callens T, Messiaen L, et al. BAX expression is a candidate prognostic and predictive marker of colorectal cancer. J Gastrointest Oncol. 2010;1(2):76–89.PubMed
41.
Nehls O, Okech T, Hsieh CJ, Enzinger T, Sarbia M, Borchard F, et al. Studies on TP53, BAX and BCL2 protein expression and microsatellite instability in stage III (UICC) colon cancer treated by adjuvant chemotherapy: major prognostic impact of proapoptotic BAX. Br J Cancer. 2007;96(9):1409–18.PubMed
42.
Nehls O, Hass HG, Okech T, Zenner S, Hsieh CJ, Sarbia M, et al. Prognostic implications of BAX protein expression and microsatellite instability in all non-metastatic stages of primary colon cancer treated by surgery alone. Int J Colorectal Dis. 2009;24(6):655–63. doi:10.​1007/​s00384-009-0635-0.PubMedCrossRef
43.
Sturm I, Köhne CH, Wolff G, Petrowsky H, Hillebrand T, Hauptmann S, et al. Analysis of the TP53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases. J Clin Oncol. 1999;17(5):1364–74.PubMed
44.
45.
Fallik D, Borrini F, Boige V, Viguier J, Jacob S, Miquel C, et al. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res. 2003;63(18):5738–44.PubMed
46.
Paradiso A, Simone G, Lena MD, Leone B, Vallejo C, Lacava J, et al. Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancer. Br J Cancer. 2001;84(5):651–8.PubMedCrossRef
47.
Pietrantonio F, Biondani P, Milione M, Melotti F, Bertarelli G, Perrone F, et al. Lack of BAX expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients. Clin Transl Oncol. 2012. doi:10.​1007/​s12094-012-0971-3.
48.
Cascinu S, Graziano F, Catalano V, Staccioli MP, Rossi MC, Baldelli AM, et al. An analysis of TP53, BAX and vascular endothelial growth factor expression in node-positive rectal cancer. Relationships with tumour recurrence and event-free survival of patients treated with adjuvant chemoradiation. Br J Cancer. 2002;86(5):744–9.PubMedCrossRef
49.
Tsamandas AC, Kardamakis D, Petsas T, Zolota V, Vassiliou V, Matatsoris T, et al. BCL2, BAX and TP53 expression in rectal adenocarcinoma. Correlation with classic pathologic prognostic factors and patients’ outcome. In Vivo. 2007;21(1):113–8.PubMed
50.
Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. German Rectal Cancer Study Group. N Engl J Med. 2004;351(17):1731–40.PubMedCrossRef
51.
Valentini V, van Stiphout RG, Lammering G, Gambacorta MA, Barba MC, Bebenek M, et al. Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol. 2011;29(23):3163–72.PubMedCrossRef
52.
Vecchio FM, Valentini V, Minsky BD, Padula GD, Venkatraman ES, Balducci M, et al. The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. Int J Radiat Oncol Biol Phys. 2005;62(3):752–60.PubMedCrossRef
53.
Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, et al. Pathological assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73(11):2680–6.PubMedCrossRef
54.
Chang HJ, Jung KH, Kim DY, Jeong SY, Choi HS, Kim YH, et al. BAX, a predictive marker for therapeutic response to preoperative chemoradiotherapy in patients with rectal carcinoma. Hum Pathol. 2005;36:364–71.PubMedCrossRef
55.
56.
Edden Y, Wexner SD, Berho M. The use of molecular markers as a method to predict the response to neoadjuvant therapy for advanced stage rectal adenocarcinoma. Colorectal Dis. 2011;14:555–61.CrossRef
57.
Sturm I, Rau B, Schlag PM, Wust P, Hildebrandt B, Riess H, et al. Genetic dissection of apoptosis and cell cycle control in response of colorectal cancer treated with preoperative radiochemotherapy. BMB Cancer. 2006;6:124.CrossRef
58.
Sigusa S, Tanaka K, Toiyama Y, Matsushita K, Kawamura M, Okugawa Y, et al. Gene expression profiles of tumor regression grade in locally advanced rectal cancer after neoadjuvant chemoradiotherapy. Oncol Rep. 2012;28:855–61.
59.
Freidlin B, McShane LM, Korn EL. Randomized clinical trials with biomarkers: design issues. J Natl Cancer Inst. 2010;102:152–60.PubMedCrossRef
60.
Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol. 1999;17:2941–53.PubMed
Metadata
Title
Role of BAX for outcome prediction in gastrointestinal malignancies
Authors
Filippo Pietrantonio
Pamela Biondani
Elisa Ciurlia
Giuseppe Fanetti
Anna Tessari
Gaia Bertarelli
Ilaria Bossi
Valeria Musella
Flavia Melotti
Maria Di Bartolomeo
Francesca Valvo
Alessandro Pellegrinelli
Massimo Milione
Federica Perrone
Filippo de Braud
Publication date
01-09-2013
Publisher
Springer US
Published in
Medical Oncology / Issue 3/2013
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-013-0610-z

Other articles of this Issue 3/2013

Medical Oncology 3/2013 Go to the issue

Original Paper

Comparison between zoledronic acid and clodronate in the treatment of prostate cancer patients with bone metastases

Original Paper

Decreased expression of DUSP4 is associated with liver and lung metastases in colorectal cancer

Original Paper

Bone metastasis from breast cancer involves elevated IL-11 expression and the gp130/STAT3 pathway

Letter to the Editor

Enhanced SOX10 and KIT expression in cutaneous melanoma

Original Paper

Haplotype structures and functional polymorphic variants of the drug target enzyme aromatase (CYP19A1) in South Indian population

Original Paper

Oligonucleotide suppression of bcl-2 in LNCaP cells is compensated by increased androgen sensitivity, p53 and oncogene activity, and suppressed caspase-3
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits